Edition:
United States

Ablynx NV (ABLX.OQ)

ABLX.OQ on NASDAQ Stock Exchange Global Select Market

23.93USD
11:28am EST
Change (% chg)

$-0.04 (-0.17%)
Prev Close
$23.97
Open
$24.19
Day's High
$24.19
Day's Low
$23.91
Volume
5,966
Avg. Vol
--
52-wk High
$24.24
52-wk Low
$17.75

Latest Key Developments (Source: Significant Developments)

Ablynx 9-month revenues decrease to 44.7 million euros ​
Thursday, 16 Nov 2017 01:21am EST 

Nov 16 (Reuters) - ABLYNX NV : :9 MONTH REVENUES OF EUR 44.7 MILLION (2016: EUR 68.9 MILLION)​.9 MONTH ‍OPERATING LOSS OF EUR 42.1 MILLION (2016: EUR 13.6 MILLION)​.‍9 MONTH NET CASH BURN OF EUR 26.9 MILLION (2016: EUR 44.1 MILLION)​.9 MONTH ‍CASH POSITION OF EUR 208.6 MILLION (2016: EUR 263.6 MILLION)​.‍9 MONTH ENDED WITH NET LOSS OF EUR 45.8 MILLION (2016: NET PROFIT OF EUR 10.9 MILLION)​.  Full Article

Ablynx announces full exercise of underwriters' option to purchase additional shares
Friday, 27 Oct 2017 01:21am EDT 

Oct 27 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES AND END OF STABILIZATION PERIOD.‍GREENSHOE OPTION GRANTED TO UNDERWRITERS FOR PURCHASE OF UP TO AN ADDITIONAL 1,714,500 NEW ORDINARY SHARES​.‍GREENSHOE EXERCISE BRINGS TOTAL GROSS PROCEEDS FOR OFFERING TO APPROXIMATELY $230 MILLION (EUR 195 MILLION)​.  Full Article

Ablynx ADS open at $17.85 in debut, 2 pct above IPO price ‍​
Wednesday, 25 Oct 2017 10:11am EDT 

Oct 25 (Reuters) - :Ablynx ADS open at $17.85 in debut on the NASDAQ versus IPO price of $17.50 per ADS‍‍​.  Full Article

Ablynx prices $200 mln IPO in the United States
Tuesday, 24 Oct 2017 08:08pm EDT 

Oct 24 (Reuters) - Ablynx NV : :Ablynx prices $200 million initial public offering in the United States.Ablynx NV - ‍prices us IPO totaling $200 million proceeds from sale of 11.43 million shares in form of American depositary shares at price of $17.50/ADS​.  Full Article

Ablynx NV now sees IPO of up to 9.5 mln ordinary shares
Tuesday, 24 Oct 2017 11:00am EDT 

Oct 24 (Reuters) - Ablynx NV :Ablynx NV now sees IPO of up to 9.5 million ordinary shares including 8.1 million ordinary shares in form of American Depositary Shares - sec filing.Ablynx NV now expects initial public offering price of ADSS will be between $17.90 and $19.08 per ADS.Ablynx NV says had previously expected IPO of up to 9.2 million ordinary shares including 7.9 million ordinary shares in form of American Depositary Shares.  Full Article

Ablynx NV offers 9.2 million of its ordinary shares in global offering
Friday, 20 Oct 2017 09:41am EDT 

Oct 20 (Reuters) - Ablynx Nv :Ablynx NV sees offering of 9.2 million of its ordinary shares in a global offering - SEC filing.Co is offering 7.9 million ordinary shares in form of ADS to investors in the United States and Canada.  Full Article

Ablynx to offer and sell about $175 million of its ordinary shares
Tuesday, 17 Oct 2017 07:30am EDT 

Oct 17 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES LAUNCH OF PROPOSED GLOBAL OFFERING.‍INTENDS TO OFFER AND SELL ABOUT $175 MILLION OF ITS ORDINARY SHARES IN A GLOBAL OFFERING​.‍BOFA MERRILL LYNCH, J.P. MORGAN AND JEFFERIES ARE ACTING AS JOINT BOOK-RUNNING MANAGERS FOR OFFERING​.‍INVESTORS OTHER THAN QUALIFIED INVESTORS UNDER APPLICABLE LAW WILL NOT BE ELIGIBLE TO PARTICIPATE IN THIS PRIVATE PLACEMENT​.‍BAIRD, BRYAN, GARNIER & CO. AND LADENBURG THALMANN ARE ACTING AS CO-MANAGERS FOR OFFERING​.‍FINAL PRICE PER SHARE OF ORDINARY SHARES TO BE DETERMINED FOLLOWING BOOKBUILDING PROCESS​.  Full Article

Ablynx establishes subsidiary in USA
Monday, 16 Oct 2017 01:00am EDT 

Oct 16 (Reuters) - ABLYNX NV ::ABLYNX ESTABLISHES SUBSIDIARY IN THE USA AND APPOINTS A GENERAL MANAGER.  Full Article

Ablynx NV files for U.S. IPO of up to $150 mln
Monday, 2 Oct 2017 05:00pm EDT 

Oct 2 (Reuters) - Ablynx NV :Ablynx NV files for U.S. IPO of up to $150.0 million ‍- SEC filing‍​.Ablynx NV says intends to apply to list ADSs on Nasdaq Global Select Market under symbol “ABLX”.Ablynx NV says BofA Merrill lynch, J.P. Morgan, Jefferies, Baird ,Bryan, Garnier & Co and Ladenburg Thalmann are underwriters to IPO.Ablynx NV - proposed IPO price is an estimate solely for purpose of calculating SEC registration fee.  Full Article

Ablynx lowers net cash burn guidance for the full year 2017
Thursday, 24 Aug 2017 01:00am EDT 

Aug 24 (Reuters) - ABLYNX NV ::ABLYNX ANNOUNCES 2017 HALF YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE.H1 REVENUES OF €34.7 MILLION (2016: €53.1 MILLION).H1 OPERATING LOSS OF €24.8 MILLION (2016: €2.0 MILLION).H1 NET CASH BURN OF €30.9 MILLION (2016: €19.0 MILLION).H1 CASH POSITION OF €204.5 MILLION (2016: €288.7 MILLION).ON TRACK TO REPORT TOPLINE RESULTS FROM THE PHASE III HERCULES STUDY OF CAPLACIZUMAB IN PATIENTS WITH ATTP IN LATE Q3 2017.EXPECTS TO REPORT RESULTS OF ONGOING SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE SUBJECTS BEFORE END OF YEAR.IN Q4 2017, CO PLANS TO FILE FOR REGULATORY APPROVAL TO ENABLE A PHASE II STUDY IN JAPAN WITH ALX-0171 IN INFANTS HOSPITALISED WITH A RSV INFECTION.COMPANY IS LOWERING ITS NET CASH BURN GUIDANCE FOR THE FULL YEAR 2017 AND IT IS NOW EXPECTED TO BE IN THE RANGE OF €65-75 MILLION.IN Q4 2017, WILL ALSO FILE FOR REGULATORY APPROVALS TO ENABLE GLOBAL PHASE II STUDY WITH ALX-0171 IN ADULTS WHO UNDERWENT STEM CELL TRANSPLANTATION AND BECAME INFECTED WITH RSV.  Full Article

BRIEF-Ablynx Reports Additional Clinically Important Benefits Of Caplacizumab

* ABLYNX REPORTS ADDITIONAL CLINICALLY IMPORTANT BENEFITS OF CAPLACIZUMAB FROM ITS PHASE III HERCULES STUDY IN ACQUIRED TTP